Citations

Clear

904 citation(s) found for "Gordon, S".

Representation of Women on Plastic Surgery Journal Editorial Boards in the United States
Pflibsen, Lacey R. , Foley, Brittany M., Bernard, Robert W. , Lee, Gordon K. , Neville, Matthew R., Almader‐Douglas, Diana , Noland, Shelley S.

Mayo Clinic

Aesthetic Surgery Journal | January 25, 2021 | Volume: 41 | Issue: 7 | Pages: NP914-NP920

10.1093/asj/sjab034 | PMID 33491085 Get It

Abstract Background During the past decade, a growing number of women have pursued medical careers, including in plastic surgery. However, female physicians have tended to be underrepresented in a variety of leadership roles in their respective specialties. Objectives The authors sought to evaluate the representation of female plastic surgeons on the editorial boards of high-impact plastic surgery journals. Methods The gender of editorial board members on 3 high-impact plastic surgery journals was evaluated from 2009 and 2018. The number of women on each editorial board was then compared with the number of board-certified female plastic surgeons (BCFPS) and board-certified female academic plastic surgeons (BCFAPS), a subgroup of BCFPS. Results There were 555 unique editorial board members from Plastic and Reconstructive Surgery, Aesthetic Surgery Journal, and Annals of Plastic Surgery from 2009 to 2018. During that period, 72 editors (13.0%) were women. At the beginning of the study, there were significantly fewer female editors than expected based on proportionate representation of BCFPS and BCFAPS to all board-certified plastic surgeons (P = 0.007 and 0.007, respectively). During the study, there was a 177% increase in women holding editorial board positions. At study end, women were adequately represented on all 3 editorial boards compared with their population data (BCFPS and BCFAPS). Conclusions During the 10 years of this study (2009-2018), editorial boards have overcome the underrepresentation of women on, and female plastic surgeons are currently adequately represented on the top 3 high-impact journal editorial boards.
Modeling autosomal dominant Alzheimer's disease with machine learning
Luckett, Patrick H. , McCullough, Austin , Gordon, Brian A. , Strain, Jeremy F. , Flores, Shaney , Dincer, Aylin , Kuffner, Todd A. , Stern, Ari, Meeker, Karin L. , Berman, Sarah , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Cash, David M. , Fulham, Michael , Jack, Clifford R. , Vöglein, Jonathan , Klunk, William E. , Oh, Hwamee , Swisher, Laura, Marcus, Daniel S. , Koudelis, Deborah, Joseph‐Mathurin, Nelly , Cash, Lisa, Hornbeck, Russ C. , Perrin, Richard J. , Hassenstab, Jason , Morris, John C. , Bateman, Randall J. , (DIAN), for the Dominantly Inherited Alzheimer Network, Wang, Qing , Cruchaga, Carlos , Jack, Clifford R , Gordon, Brian A , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Cash, David M , Berman, Sarah , McCarthy, John Edward , Jucker, Mathias , Schofield, Peter R. , Brickman, Adam M. , Brooks, William S. , Ghetti, Bernardino , Koeppe, Robert A. , Su, Yi , Weiner, Michael W. , Wáng, Qīng , Xiong, Chengjie , Karch, Celeste M. , McDade, Eric , Benzinger, Tammie L.S. , Ances, Beau M. , (DIAN), for the Dominantly Inherited Alzheimer Network, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | January 21, 2021 | Volume: 17 | Issue: 6 | Pages: 1005-1016

10.1002/alz.12259 | PMID 33480178 Get It

AbstractIntroductionMachine learning models were used to discover novel disease trajectories for autosomal dominant Alzheimer's disease.MethodsLongitudinal structural magnetic resonance imaging, amyloid positron emission tomography (PET), and fluorodeoxyglucose PET were acquired in 131 mutation carriers and 74 non‐carriers from the Dominantly Inherited Alzheimer Network; the groups were matched for age, education, sex, and apolipoprotein ε4 (APOE ε4). A deep neural network was trained to predict disease progression for each modality. Relief algorithms identified the strongest predictors of mutation status.ResultsThe Relief algorithm identified the caudate, cingulate, and precuneus as the strongest predictors among all modalities. The model yielded accurate results for predicting future Pittsburgh compound B (R2 = 0.95), fluorodeoxyglucose (R2 = 0.93), and atrophy (R2 = 0.95) in mutation carriers compared to non‐carriers.DiscussionResults suggest a sigmoidal trajectory for amyloid, a biphasic response for metabolism, and a gradual decrease in volume, with disease progression primarily in subcortical, middle frontal, and posterior parietal regions.
Gastric ablation as a novel technique for modulating electrical conduction in the in vivo stomach
Aghababaie, Zahra , Paskaranandavadivel, Niranchan , Chan, Chih-Hsiang Alexander , Du, Peng , Asirvatham, Samuel J. , Farrugia, Gianrico , O’Grady, Gregory , Cheng, Leo K. , Angeli, Timothy R. , Farrugia, Gianrico , Angeli-Gordon, Timothy R , Asirvatham, Samuel J , Paskaranandavadivel, Niranchan , Amirapu, Satya , Beyder, Arthur

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | January 20, 2021 | Volume: 320 | Issue: 4 | Pages: G573-G585

10.1152/ajpgi.00448.2020 | PMID 33470186 Get It

This study presents gastric ablation as a new method for modulating slow wave activation and propagation in vivo, by creating localized electrical conduction blocks in the stomach, validated by high-resolution electrical mapping and histological tissue analysis. The results define the effective energy dose range for creating conduction blocks, while maintaining the mucosal and submucosal integrity, and demonstrate the electrophysiological effects of ablation. In future, gastric ablation can now be translated toward disrupting dysrhythmic slow wave activation.
Flortaucipir (tau) PET in LGI1 antibody encephalitis
Day, Gregory S. , Gordon, Brian A. , McCullough, Austin , Bucelli, Robert C. , Perrin, Richard J. , Gordon, Brian A , Day, Gregory S , Benzinger, Tammie L.S. , Ances, Beau M.

Mayo Clinic

Annals of Clinical and Translational Neurology | January 10, 2021 | Volume: 8 | Issue: 2 | Pages: 491-497

10.1002/acn3.51297 | PMID 33410601 Get It

AbstractThe contributors to persistent cognitive impairment and hippocampal atrophy in leucine‐rich glioma‐inactivated 1 antibody encephalitis (LGI1) patients are unknown. We evaluated whether tau neuropathology measured with [18F]flortaucipir PET neuroimaging associated with persistent cognitive impairment and hippocampal atrophy in four recovering LGI1 patients (3 men; median age, 67 [37–88] years). Imaging findings in cases were compared with those observed in age‐ and gender‐similar cognitively normal individuals (n = 124) and individuals with early‐symptomatic Alzheimer disease (n = 11). Elevated [18F]flortaucipir retention was observed in the two LGI1 patients with hippocampal atrophy and persistent cognitive impairment, including one with autopsy‐confirmed Alzheimer disease. Tau neuropathology may associate with cognitive complaints and hippocampal atrophy in recovering LGI1 patients.
Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations
Itan, Michal, Grass, Daniel, Gordon, Yaara , Dolitzky, Avishay, Hazut, Inbal, Avlas, Shmuel , Jacobsen, Elizabeth A. , Ziv‐Baran, Tomer , Munitz, Ariel , Munitz, Ariel , Jacobsen, Elizabeth A , Grisaru‐Tal, Sharon , Torres–Roca, Javier F. , Eschrich, Steven A

Mayo Clinic

OncoImmunology | December 31, 2020 | Volume: 10 | Issue: 1 | Pages: No page available

10.1080/2162402x.2020.1859732 | PMID 33457078 Get It

The influence of interstitial cells of Cajal loss and aging on slow wave conduction velocity in the human stomach
Wang, Tim Hsu‐Han , Angeli, Timothy R. , Ishida, Shunichi , Du, Peng , Gharibans, Armen A. , Paskaranandavadivel, Niranchan , Miyagawa, Taimei , Farrugia, Gianrico , Cheng, Leo K. , O’Grady, Gregory , Angeli-Gordon, Timothy R , Paskaranandavadivel, Niranchan , Gharibans, Armen A , Imai, Yohsuke , Abell, Thomas L.

Mayo Clinic

Physiological Reports | December 24, 2020 | Volume: 8 | Issue: 24 | Pages: No page available

10.14814/phy2.14659 | PMID 33355992 Get It

Results of surgical resection of carotid body tumors: A twenty-year experience
Moore, January , Casler, John D., Oldenburg, W. Andrew, Reimer, Ronald, Wharen, Robert E. , Deen, H. Gordon , Farres, Houssam , Hakaim, Albert G., Moore, January , Oldenburg, Warner Andrew

Mayo Clinic

Rare Tumors | December 22, 2020 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/2036361320982813 | PMID 33425309 Get It

This study examines whether surgical resection of carotid body tumors (CBTs) is acceptable in light of potential significant neurologic complications. This IRB-approved retrospective study analyzed data from 24 patients undergoing surgical treatment for CBTs between April 1998 and April 2017 at Mayo Clinic (Florida campus only). For patients who underwent multiple CBT resections, only data from the first surgery was used in this analysis. CBT resection occurred in 24 patients with the following demographics: fourteen patients (58.3%) were female, median age was 56.5 years, median BMI was 29. A prior history of neoplasm was found in ten patients (41.7%). A known family history of paraganglioma was present in five patients (20.8%). Two patients were positive for succinate dehydrogenase mutation (8.3%). Multiple paragangliomas were present in seven patients (29.2%). There was nerve sacrifice in three patients (12.5%) during resection. Carotid artery reconstruction and patch angioplasty occurred in one patient (4.2%). Complete resection occurred in 24 patients (100.0%). Postoperatively, one patient (4.2%) suffered stroke. No mortalities occurred within or beyond 30 days of surgery. Persistent cranial nerve injury occurred in two patients (8.3%) with vocal cord paralysis. There was no recurrence of CBT through last follow-up. Five patients (20.8%) were diagnosed with other neoplasms after resection, including basal cell carcinoma, contralateral carotid body tumor, glomus vagale, and glomus jugulare. There was 100% survival at 1 year in patients followed for that time ( n = 17). Surgical treatment remains the first-line curative treatment to relieve symptoms and ensure non-recurrence. While acceptable, neurologic complications are significant and therefore detailed preoperative informed consent is mandatory.
Factors associated with complete clip closure after endoscopic mucosal resection of large colorectal polyps
Pohl, Heiko , Ortíz, Oswaldo , Rex, Douglas K. , Moyer, Matthew T. , Hasan, Muhammad K. , Pleskow, Douglas K. , Elmunzer, B. Joseph , Khashab, Mouen A., Al-Kawas, Fíras H. , Gordon, Stuart R. , Abraham, Mathew , Levenick, John M. , Aslanian, Harry R., Renteln, Daniel von , Rastogi, Amit , Gill, Jeffrey, Law, Ryan , Wallace, Michael B. , Elias, Pooja A., MacKenzie, Todd A. , Ortiz, Oswaldo , Pleskow, Douglas , Antaki, Fadi , von Renteln, Daniel , Wallace, Michael B , Pellisé, Maria , Grimm, Ian S. , Khashab, Mouen A. , Sanaei, Omid , Mathew, Abraham, Crockett, Seth D.

Mayo Clinic

Endoscopy | December 9, 2020 | Volume: 53 | Issue: 11 | Pages: 1150-1159

10.1055/a-1332-6727 | PMID 33291159 Get It

Abstract Background and study aim Delayed bleeding is a common adverse event following endoscopic mucosal resection (EMR) of large colorectal polyps. Prophylactic clip closure of the mucosal defect after EMR of nonpedunculated polyps larger than 20 mm reduces the incidence of severe delayed bleeding, especially in proximal polyps. This study aimed to evaluate factors associated with complete prophylactic clip closure of the mucosal defect after EMR of large polyps. Methods This is a post hoc analysis of the CLIP study (NCT01936948). All patients randomized to the clip group were included. Main outcome was complete clip closure of the mucosal resection defect. The defect was considered completely closed when no remaining mucosal defect was visible and clips were less than 1 cm apart. Factors associated with complete closure were evaluated in multivariable analysis. Results In total, 458 patients (age 65, 58 % men) with 494 large polyps were included. Complete clip closure of the resection defect was achieved for 338 polyps (68.4 %); closure was not complete for 156 (31.6 %). Factors associated with complete closure in adjusted analysis were smaller polyp size (odds ratio 1.06 for every millimeter decrease [95 % confidence interval 1.02–1.08]), good access (OR 3.58 [1.94–9.59]), complete submucosal lifting (OR 2.28 [1.36–3.90]), en bloc resection (OR 5.75 [1.48–22.39]), and serrated histology (OR 2.74 [1.35–5.56]). Conclusions Complete clip closure was not achieved for almost one in three resected large nonpedunculated polyps. While stable access and en bloc resection facilitate clip closure, most factors associated with clip closure are not modifiable. This highlights the need for alternative closure options and measures to prevent bleeding.
Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab
Clifford, David B., Coalier, Kelley A., Fagan, Anne M. , Farlow, Martin R. , Mills, Susan , Salloway, Stephen , Santacruz, Anna , Wang, Guoqiao , Snider, B. Joy, Mummery, Catherine J. , Surti, Ghulam M., Hannequin, Didier , Jiménez‐Velázquez, Ivonne Z. , Dyck, Christopher H. van , Gauthier, Serge , Galasko, Doug, Jayadev, Suman , Formaglio, Maïté, Clarnette, Roger, Pariente, Jérémie , Dubois, Bruno, Andersen, Scott W. , Holdridge, Karen C. , Mintun, Mark A., Sims, John R. , Yaari, R. , Baudler, Monika, Doody, Rachelle S., Fontoura, Paulo , Kerchner, Geoffrey A. , Team, DIAN‐TU Study, Bateman, Randall J. , Aschenbrenner, Andrew J. , Benzinger, Tammie L.S. , Cruchaga, Carlos , Goate, Alison , Gordon, Brian A. , Hassenstab, Jason , Jack, Clifford R. , Koeppe, Robert A. , McDade, Eric , Morris, John C. , Snyder, Peter J. , Xiong, Chengjie , Wallon, David , Berman, Sarah , Lah, James J. , Roberson, Erik D. , Honig, Lawrence S. , Sánchez‐Valle, Raquel , Brooks, William S. , Masters, Colin L. , Brosch, Jared R. , Hsiung, Ging‐Yuek Robin , Masellis, Mario , Dubois, Bruno, Pasquier, Florence , Delmar, Paul , Team, DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S9 | Pages: No page available

10.1002/alz.041129 Get It

AbstractBackgroundAlzheimer’s disease (AD) prevention trials aim to intervene prior to significant neuronal loss, brain damage, and symptom onset to delay or slow cognitive decline. In dominantly inherited AD (DIAD), mutation carriers develop symptomatic AD at predictable ages with near 100% penetrance. In 2012, the Dominantly Inherited Alzheimer Network Trials Unit Adaptive Prevention Trial (DIAN‐TU APT) platform launched a double‐blind, randomized, placebo‐controlled, parallel group trial of two anti‐amyloid‐beta monoclonal antibodies with two different antigenic targets, gantenerumab and solanezumab (NCT01760005). The DIAN‐TU scientific development, implementation of the first AD prevention trial, trial challenges and opportunities, including dose escalation, and top‐line results will be presented.MethodDIAN was established in 2008 in response to a call from the National Institute of Aging to establish a network to study DIAD and enable future clinical trials. Successive breakthroughs in understanding disease processes enabled the launch of the DIAN‐TU adaptive prevention trial, a global adaptive platform trial supporting testing multiple drugs in parallel. The DIAN‐TU partners include patients and families at risk for DIAD, global academic researchers, the NIH, Alzheimer’s Association, philanthropic supporters, the DIAN‐TU Pharma Consortium, and pharmaceutical companies with drugs being tested. Important milestones include developing a platform to enable a comprehensive efficient treatment trial for this rare population, adding tau PET as part of AMP AD, adapting dosing mid‐trial and extending the original biomarker trial to continue randomized dosing to test a cognitive endpoint until the last patient reaches 4 years, developing a disease progression statistical model and inclusion of DIAN observational data to increase the power to determine drug effects.ResultThe primary and key secondary outcomes of the DIAN‐TU trial will be presented for each therapy in the context of targeting amyloid‐beta at pre‐clinical and clinically symptomatic stages of disease.ConclusionThese results inform about AD hypotheses, timing of treatment and the prospect of slowing, or preventing AD in DIAD and sporadic AD.